Psilera Bioscience

Executive Summary

Psilera Bioscience is a Tampa-based biotechnology company founded in 2019, specializing in the discovery and development of next-generation neuroplastogens—novel small molecules aimed at treating neurological disorders. The company leverages its extensive proprietary compound library to create at-home therapy options, with the goal of revolutionizing mental healthcare. Psilera’s approach focuses on early-stage drug development, targeting conditions that currently have limited treatment options. As a private, early-stage entity, the company has not yet disclosed detailed financials or clinical pipeline specifics, but its innovative platform and focus on neuroplastogens position it within the rapidly growing psychedelic-derived therapeutics space. The company's progress will depend on advancing its lead candidates through preclinical and clinical development, securing partnerships, and obtaining regulatory approvals.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Neuroplastogen Candidate40% success
• Q2 2026Preclinical Proof-of-Concept Data Readout60% success
• Q3 2026Series A Funding Announcement50% success